Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: The black rhinos died of salt poisoning following the decision by the Kenya Wildlife Service (KWS) to ignore water test results in Tsavo East National Park, the committee’s report said. The deaths of the endangered animals, being moved to a more secure home in the face of the threat from poachers, were a major embarrassment to Kenya, which sells itself as destination for wildlife tourism. The inquiry said WWF, which donated $1 million for the relocation in June 2018, applied pressure on KWS to speed up the process in a bid to generate positive publicity and secure funding for itself from Germany. WWF denied the allegations in the inquiry report, which was made public last week, saying KWS had carried out hydrological surveys and given assurances the park was safe and suitable. “At no point either before or during the translocations were any issues raised about the quality of the water on the site,”  WWF said by email. “We would never push for a translocation to go ahead against the recommendations of the relevant experts. This was a tragedy we hope will never be repeated.”  The parliamentary committee’s inquiry said the relocation took place during a period in 2018 when the term of one KWS board had ended and before a new one had begun, creating a lack of oversight. The report said KWS’s former board of trustees had rejected the relocation three times in part because of the high salinity levels of the drinking water in the park. The report said Najib Balala, the minister of tourism and wildlife, should take overall responsibility for the rhinos’ deaths because he delayed the appointment of the new KWS board. The minister’s spokesman declined to comment. The KWS could not be immediately reached to comment. However, Richard Leakey, former chairperson of KWS, told the inquiry: “WWF-Kenya, as the funding entity, was alleged to have had a major interference on the board resolution against the translocation, and consequently pushed for the exercise after the exit of the board.”  WWF said it was saddened by the loss of the rhinos and it fully recognized the “serious failings of this operation”. “In response, we have strengthened existing practices and implemented brand new organizational guidelines to mitigate future risk as far as possible.”  Kenya had a rhino population of 1,258 in 2017 of which 745 were black rhinos, 510 were southern white rhinos and three were northern white rhinos, having grown from less than 400 rhinos in the 1980s. Poaching has risen in recent years across sub-Saharan Africa where well-armed criminal gangs have killed elephants for tusks and rhinos for horns. Often the animal parts are shipped to Asia for use in ornaments and medicines. Claim: WWF says it did not push for rhino relocation process where 11 died.
Example Output: The World Wildlife Fund has rejected the findings of a Kenyan parliamentary inquiry that said the conservation group pushed Kenyan authorities to speed up a botched relocation of 14 rhinos last year that led to the deaths of 11 animals.

Example Input: Paragraph: "The story mentions that 30 capsules of OSR#1 cost $60. It would have been nice had the story also included information about the amount of active ingredient per capsule and the manufacturer’s recommended dosage. This would have allowed readers to make a better calculation as to the financial impact of treatment. This is critical information considering these costs will be borne out of pocket by anyone using OSR #1. The story juxtaposes a light-hearted ""success story"" with information about the industrial uses of OSR #1 for removing toxic heavy metals from contaminated soil. This is a clever way of way of emphasizing that the use of this product is based entirely on anecdote. The story clearly states that there is no credible evidence supporting the efficacy of the product. The harms of this product are impossible to quantify, given that it doesn’t seem to have been studied in humans or in animals. The story notes that other chelating drugs carry ""significant risks"" and ""can strip the body of metals necessary for health."" It would have been nice to see more specifics about what chelators can do, but the story satisfies the critierion. The story states that medical searches turned up no papers about OSR#1, and that the company which makes the product provided no published studies about its use. The story rightly suggests that this total lack of evidence should be deeply troubling. The story doesn’t exaggerate the prevalence or severity of autism, or of the potentially toxic compounds sometimes used to treat it. The story quotes multiple experts on pharmacology and an FDA spokesperson. It also quotes from an interview with Boyd Haley, president of the company which makes OSR #1. It attempted to get a reaction from Kim Stagliano, an OSR #1 proponent, but this effort was not successful. While the story mentions that there other are chelation drugs out there, it could have mentioned that there are educational strategies which can be helpful for children with autism and which have better evidence to support their use. The story states that OSR#1 is, according to the manufacturer’s website, available only through dentists’ or doctors’ offices. It notes, however, that the Tribune was able to buy 30 capsules of the product directly from a compounding pharmacy listed on the site. We are impressed that the Tribune went to these lengths to establish the product’s availability. The story provides a fairly detailed pedigree for OSR #1 and discusses its similarity to other chelation therapies used in the treatment of autism. It also gives credit to blogger Kathleen Seidel for being the first to raise concerns about OSR #1 in her blog, Neurodiversity.com The story is well sourced and is not based on a press release." Claim: Industrial chemical OSR#1 used as autism treatment
Example Output: "The product known as OSR #1 contains a chemical originally intended for clean-up of toxic waste at industrial sites. This story by the Chicago Tribune (which was republished by the Los Angeles Times) examines how, despite a total lack of any research on the product in humans, OSR #1 ended up being marketed as a ""dietary supplement"" for children with autism. The story does an especially good job of pointing out the regulatory gaps which can allow risky, poorly researched products to be sold as ""cures"" to desperate parents and caregivers. It’s an example of health journalism doing what it’s supposed to do, and doing it well. Autism is a serious disorder which affects a growing number of children and their families and for which there are few good treatment options. This is a situation ripe for abuse by overzealous advocates and unscrupulous marketers of uNPRoven therapies. As Boyd Haley, president of the company that make the the OSR#1 supplement, puts it: ""There are so many snake oil salesmen out there, it’s just incredible."""

Example Input: Paragraph: Limiting the quantity per dosage unit will reduce the risk of inadvertent overdose, which can lead to liver failure, liver transplant and death, the Food and Drug Administration said. It cited the fact that no available data showed that taking more than the recommended dose provided benefits that outweighed the added risks. (link.reuters.com/nen95v)  Inadvertent overdose from combination drugs containing acetaminophen, also known as paracetamol in most countries outside the United States, accounts for nearly half of all cases of acetaminophen-related liver failure in the United States, the agency said. Combination acetaminophen products are commonly prescribed to patients to treat pain from acute injuries, post-operative pain, or pain following dental procedures. In January 2011, the FDA asked manufacturers of combination drugs containing acetaminophen, sold globally under trade names such as Tylenol and Panadol, to limit acetaminophen doses to no more than 325 mg in each tablet or capsule by January 14, 2014. (link.reuters.com/hyn95v)  Some of these products still remain available, the agency said. The FDA also suggested that pharmacists who receive a prescription for a combination product with more than the recommended dose contact the prescriber to discuss using a lower dose. In the near future, the FDA plans to institute proceedings to withdraw approval for combination drugs that remain on the market, it said in a statement. Acetaminophen, one of the most commonly used drugs in the United States, is widely used in both prescription and over-the-counter products to reduce pain and fever. Claim: FDA asks doctors to limit acetaminophen in combination drugs.
Example Output:
U.S. health regulators recommended on Tuesday that healthcare professionals stop prescribing combination drugs that contain more than 325 milligrams of acetaminophen per tablet, capsule, or other dosage unit, citing the risk of liver damage.